Trial Search Results

Pain Control Following Sinus Surgery

Given the ongoing national opioid epidemic, an increased interest has developed in optimizing opioid prescribing practices of physicians, including otolaryngologists. Endoscopic sinus surgery (ESS) is one of the most commonly performed surgeries by otolaryngologists with over 250,000 ESS's performed annually in the U.S. Multiple studies have shown that, compared to the amount patients actually consume, otolaryngologists prescribe a high quantity of opioids to patients recovering from ESS). It has been shown that these excess opioid medications contribute to prolonged use or abuse by the patient, family members, or friends. The purpose of this study is to better understand the pain management requirements of patients who undergo ESS for recurrent acute rhinosinusitis (RARS) or chronic rhinosinusitis (CRS).

This prospective, randomized, multi-institutional controlled trial will aim to determine the degree to which pain following ESS can be adequately controlled by non-opioid medications. It will also determine whether post-ESS narcotic use can be avoided entirely, or at least significantly limited. Patients will be randomized into two groups, each of which will receive a stepwise analgesic regimen consisting of acetaminophen and oxycodone or acetaminophen and ibuprofen. Pain will be assessed daily using visual analog scales (VAS) and the Brief Pain Inventory (BPI).

The results of this study will help to develop a standardized approach to pain management in the post-ESS setting and help to elucidate the role of non-opioid pain medications. The ultimate goal would be to positively affect opioid prescribing patterns among surgeons who perform ESS in order to significantly reduce the quantity of opioids prescribed to patients while continuing to adequately manage patients' pain.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: NorthShore University HealthSystem

Stanford Investigator(s):

Intervention(s):

  • Drug: OxyCODONE 5 Mg Oral Tablet
  • Drug: Ibuprofen 600 Mg Oral Tablet
  • Drug: Acetaminophen 650 MG Oral Tablet

Phase:

Phase 4

Eligibility


Inclusion Criteria:

   - 18 years or older

   - English-speaking

   - Scheduled to undergo endoscopic sinus surgery for sinusitis (CRSwNP, CRSsNP, or RARS)

   - Can commit to follow up for at least one postoperative visit

Exclusion Criteria:

Patients undergoing a septorhinoplasty (septoplasty permissible if patient will also
undergo sinus surgery)

   - Doyle splints to be used

   - Alcohol or opioid use disorder

   - History of chronic pain disorders

   - Regular use of acetaminophen/NSAIDS (>4x per week)

   - Patients who use narcotics or neuromodulating drugs (e.g. gabapentin,
   nortriptyline)more than 2x per week on average.

   - Gastrointestinal ulcers or bleeding

   - Chronic kidney disease/known decreased renal function (estimated glomerular filtration
   rate <60)

   - Liver cirrhosis or other hepatic impairment

   - Prior adverse reaction to opioids or NSAIDS

   - Other contraindications to any drug classes in either group.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Noel F Ayoub, MD MBA
Not Recruiting